Format

Send to

Choose Destination
Leuk Lymphoma. 2016 Aug;57(8):1814-22. doi: 10.3109/10428194.2016.1140164. Epub 2016 Feb 17.

Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.

Author information

1
a Section of Hematology, Department of Medicine , Kungälvs Hospital, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden ;
2
b Swedish NMR Centre, University of Gothenburg , Gothenburg , Sweden ;
3
c Department of Research , Development and Education, Region Halland , Gothenburg , Sweden ;
4
d Section of Hematology and Coagulation, Sahlgrenska University Hospital, Sahlgrenska Academy at the University of Gothenburg , Gothenburg , Sweden ;
5
e Computational Life Science Cluster, Department of Clinical Chemistry , Umeå University, Umeå and Bioinformatics for Life Sciences (BILS) , Gothenburg , Sweden ;
6
f Unit of Hematology, Department of Medicine , Södra Älvsborg Hospital Borås, Sahlgrenska Academy at the University of Gothenburg , Gothenburg , Sweden.

Abstract

The prognosis for diffuse large B-cell lymphoma (DLBCL) patients with early relapse or refractory disease is dismal. To determine if clinical outcome correlated to diverse serum metabolomic profiles, we used (1)H nuclear magnetic resonance (NMR) spectroscopy and compared two groups of DLBCL patients treated with immunochemotherapy: i) refractory/early relapse (REF/REL; n=27) and ii) long-term progression-free (CURED; n = 60). A supervised multivariate analysis showed a separation between the groups. Among discriminating metabolites higher in the REF/REL group were the amino acids lysine and arginine, the degradation product cadaverine and a compound in oxidative stress (2-hydroxybutyrate). In contrast, the amino acids aspartate, valine and ornithine, and a metabolite in the glutathione cycle, pyroglutamate, were higher in CURED patients. Together, our data indicate that NMR-based serum metabolomics can identify a signature for DLBCL patients with high-risk of failing immunochemotherapy, prompting for larger validating studies which could lead to more individualized treatment of this disease.

KEYWORDS:

DLBCL; metabolomics; outcome; serum

Comment in

PMID:
26887805
DOI:
10.3109/10428194.2016.1140164
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center